Dr. Timothy Wassenaar, MD
Claim this profileUW Cancer Center at ProHealth Care
Expert in Cancer
Expert in Lung Cancer
111 reported clinical trials
188 drugs studied
About Timothy Wassenaar, MD
Education:
- Received an MD from the University of Wisconsin School of Medicine and Public Health in 2015.
Experience:
- Completed a Residency in Radiation Oncology at the University of Wisconsin Hospital and Clinics in 2020.
- Undertook a Fellowship in Stereotactic Body Radiotherapy (SBRT) and Stereotactic Radiosurgery (SRS) at the same institution in 2021.
- Currently affiliated with the UW Cancer Center at ProHealth Care.
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Timothy Wassenaar, MD is currently running
Surgery and Radiation vs. Radiation Alone
for Brain Cancer
This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.
Recruiting2 awards Phase 3
Trastuzumab Emtansine
for Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab in treating patients with salivary gland cancer.
Recruiting1 award Phase 2
More about Timothy Wassenaar, MD
Clinical Trial Related5 years of experience running clinical trials · Led 111 trials as a Principal Investigator · 67 Active Clinical TrialsTreatments Timothy Wassenaar, MD has experience with
- Nivolumab
- Pembrolizumab
- Carboplatin
- Paclitaxel
- Atezolizumab
- Fluorouracil
Breakdown of trials Timothy Wassenaar, MD has run
Cancer
Lung Cancer
Adenocarcinoma
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Timothy Wassenaar, MD specialize in?
Timothy Wassenaar, MD focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Timothy Wassenaar, MD currently recruiting for clinical trials?
Yes, Timothy Wassenaar, MD is currently recruiting for 66 clinical trials in Waukesha Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Timothy Wassenaar, MD has studied deeply?
Yes, Timothy Wassenaar, MD has studied treatments such as Nivolumab, Pembrolizumab, Carboplatin.
What is the best way to schedule an appointment with Timothy Wassenaar, MD?
Apply for one of the trials that Timothy Wassenaar, MD is conducting.
What is the office address of Timothy Wassenaar, MD?
The office of Timothy Wassenaar, MD is located at: UW Cancer Center at ProHealth Care, Waukesha, Wisconsin 53188 United States. This is the address for their practice at the UW Cancer Center at ProHealth Care.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.